GlassScriptPhysician profile
Erik T Olson
NPI 1235454620
$3,580.65
in general payments reported to CMS, 2019-2025
16 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $101 · 2021: $54.28 · 2022: $252 · 2023: $935 · 2024: $923 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.11 |
| Education | $115.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $914.43 | 2020-2025 | |
| Janssen Biotech, INC. | $882.62 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $723.76 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Boston Scientific Corporation | $338.40 | 2023-2025 | Exalt Model D, Orcapod, Axios |
| Regeneron Healthcare Solutions, INC. | $256.56 | 2022-2025 | Dupixent |
| Celgene Corporation | $108.02 | 2022-2023 | Zeposia |
| Genzyme Corporation | $51.13 | 2025 | |
| Phathom Pharmaceuticals, INC. | $49.97 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.32 | 2023-2024 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $47.46 | 2025 | Iqirvo |
| Ardelyx, INC. | $45.37 | 2022-2023 | Ibsrela |
| Braintree Laboratories, INC. | $35.72 | 2024 | Sutab, Suflave |
| Gilead Sciences, INC. | $22.76 | 2024 | |
| Lilly USA, LLC | $20.01 | 2025 | Omvoh |
| Pfizer INC. | $18.65 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $16.47 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.